New Releases from NCBI BookshelfAbemaciclib (Verzenio): Reimbursement request: For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in females who are postmenopausal as initial endocrine-based therapy: Reimbursement Review [Internet].​Abemaciclib (Verzenio): Reimbursement request: For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in females who are postmenopausal as initial endocrine-based therapy: Reimbursement Review [Internet].